<DOC>
	<DOC>NCT02420392</DOC>
	<brief_summary>To investigate the effect of dapagliflozin on the incretin sensitivity of the pancreatic beta cell.</brief_summary>
	<brief_title>Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Type 2 diabetes for dapagliflozin arm Normal glucose tolerance (fasting plasma glucose &lt;100 mgd/l, HbA1c &lt;6.0%) for normal glucose tolerance arm Age 18 to 75 years BMI &lt;35 kg/m2 For type 2 diabetes patients, at least 3 months of treatment period and HbA1c 7.5 to 11.0% and treatment with lifestyle modification and/or metformin or sulfonylurea Who is allergic to dapagliflozin Type 1 diabetes Patients with history of diabetic ketoacidosis Reduced renal function (eGFR &lt;60ml/min/1.73m2) Taking loop diuretics or dehydrated patient History of hypotension when taking hypertensive medication Diagnosed with heart failure Diagnosed with cerebral infarction Taking insulin, DPP4 inhibitor, GLP1 analogue, pioglitazone, alphaglucosidase inhibitor Above upper limit of normal hematocrit range (male 3952%, female 3648%) Pregnant or breastfeeding women History of recurrent genitourinary infection AST/ALT more than two fold increased above normal upper limit Hemolytic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>